Alnylam Presents Key Pre-Clinical Proof-of-Concept Data for ALN-AS1, an RNAi …
Alnylam Presents Key Pre-Clinical Proof-of-Concept Data for ALN-AS1, an RNAi …
Filed under: drug treatment programs in maryland
Alnylam's AIP drug candidate, ALN-AS1, is part of the company's “Alnylam 5×15” product development and commercialization strategy, in which the company aims to advance five genetic disease target programs into clinical development, including programs …
Read more on Fort Mills Times
ACTELION LTD : Additional macitentan (Opsumit) data in pulmonary arterial …
Filed under: drug treatment programs in maryland
ALLSCHWIL/BASEL, SWITZERLAND – 17 May 2013 – Actelion (SIX: ATLN) today announced that further data for its investigational drug macitentan (Opsumit ®) will be presented at the American Thoracic Society (ATS) International Congress, Philadelphia, USA …
Read more on 4-traders (press release)
US FDA approves Janssen Biotech 's Simponi for treatment of ulcerative colitis
Filed under: drug treatment programs in maryland
The US Food and Drug Administration (FDA) has approved Janssen Biotech, Inc.'s Simponi (golimumab) for the treatment of moderately to severely active ulcerative colitis (UC) in adult patients who have demonstrated corticosteroid dependence or who have …
Read more on pharmabiz.com